DNA plasmid vaccine for type 1 diabetes(Stanford University)(DNA plasmid vaccine for type 1 diabetes(Stanford University))

概要

基本信息

药物类型

DNA疫苗、预防性疫苗

别名

DNA plasmid vaccine for type 1 diabetes、BHT-3021、R-7426

+ [4]

靶点

insulin

作用方式

调节剂

作用机制

INS基因调节剂

治疗领域

免疫系统疾病内分泌与代谢疾病

在研适应症-

非在研适应症

1型糖尿病

原研机构

Stanford University

在研机构-

非在研机构

Bayhill Therapeutics, Inc.

Tolerion, Inc.

权益机构

Genentech, Inc.

Bayhill Therapeutics, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 DNA plasmid vaccine for type 1 diabetes(Stanford University) 相关的临床试验

NCT03794960

/ Withdrawn临床2期

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With Established Type 1 Diabetes Mellitus

The study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial in subjects with established T1D.

开始日期2019-12-14

申办/合作机构

Tolerion, Inc.

NCT03794973

/ Withdrawn临床2期

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset Type 1 Diabetes Mellitus

The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.

开始日期2019-12-14

申办/合作机构

Tolerion, Inc.

NCT03895437

/ Terminated临床2期

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus

The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.

开始日期2019-06-17

申办/合作机构

Tolerion, Inc.

100 项与 DNA plasmid vaccine for type 1 diabetes(Stanford University) 相关的临床结果

登录后查看更多信息

100 项与 DNA plasmid vaccine for type 1 diabetes(Stanford University) 相关的转化医学

登录后查看更多信息

100 项与 DNA plasmid vaccine for type 1 diabetes(Stanford University) 相关的专利（医药）

登录后查看更多信息

2

项与 DNA plasmid vaccine for type 1 diabetes(Stanford University) 相关的文献（医药）

2010-12-01·IDrugs : the investigational drugs journal

Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USA.

作者: Garren, Hideki

The Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference, held in San Francisco, included topics covering new therapeutic developments in the field of vaccines and peptide therapies. This conference report highlights selected presentations on the development of vaccines for NSCLC, DNA delivery platforms as vaccines, vaccine combination therapy for cancer, DNA vaccines for autoimmune diseases, and improved peptide therapeutics. Investigational drugs discussed include TG-4010 (Transgene), and a series of vaccines targeting autoimmune diseases, including BHT-3021 (Bayhill/Genentech) for type I diabetes, BHT-3009 (Bayhill) for multiple sclerosis and BHT-3034 (Bayhill) for myasthenia gravis.

2009-03-01·Methods and findings in experimental and clinical pharmacology

Gateways to clinical trials.

作者: Moral, M A ; Tomillero, A

ABT-869, Acadesine, Acetylsalicylic acid/omeprazole, Adefovir, Adefovir dipivoxil, AEG-35156, Agatolimod sodium, Albiglutide, Alemtuzumab, Alipogene tiparvovec, Alogliptin benzoate, AMG-386, Amrubicin hydrochloride, Apremilast, Aripiprazole, Asoprisnil, Atorvastatin/fenofibrate, AVN-944, Axitinib; Belinostat, Bevacizumab, BHT-3021, BI-2536, Biapenem, Bilastine, Biphasic insulin aspart, Blinatumomab, Bortezomib, Bosentan; Catumaxomab, CD-NP, Cediranib, Certolizumab pegol, Cetuximab, Choline fenofibrate, Ciclesonide, CK-1827452,Clevudine, Clofarabine, CSL-360, CYT-997; Dapagliflozin, Darinaparsin, Denosumab, Densiron 68, Desloratadine, Dulanermin; Edoxaban tosilate, Emtricitabine, Entecavir, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe, Ezetimibe/simvastatin; Fidaxomicintiacumiv, Fulvestrant; G-207, GCR-8015, Gefitinib, Ghrelin (human), Glufosfamide; HPV16L1E7CVLP; Ibutamoren mesilate, Imatinib mesylate, Insulin detemir, Insulin glargine, Iodine (I131) tositumomab, Istaroxime, ITMN-191, Ixabepilone; JZP-4, Lenalidomide; Levetiracetam, Linaclotide acetate, Liposomal cytarabine/daunorubicin, Liposomal doxorubicin, Liraglutide, LY-518674; Milatuzumab, MMR-V, Motesanib diphosphate, Mycophenolic acid sodium salt; Niacin/simvastatin; Obatoclax mesylate, Odanacatib; Paclitaxel nanoparticles, Paclitaxel-eluting stent, Pazufloxacin, PBT-2, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ribavirin, Pemetrexed disodium, Perampanel, PfCP2.9, Pitavastatin calcium, Poly I:CLC, Pomalidomide, Pralatrexate, Pramlintide acetate, Prucalopride; rhGAD65, Roflumilast; RTS,S/AS02D; SCH-530348, Semagacestat, Sirolimus-eluting coronary stent, Sirolimus-Eluting Stent, SIR-Spheres, Sivelestat sodium hydrate, Sorafenib, Sunitinib malate; Tadalafil, Tafluprost, Tanespimycin, Teduglutide, Telaprevir, Telbivudine, Tenofovir disoproxil fumarate, Tiotropium bromide, TMC-435350, Tositumomab/iodine (I131) tositumomab, Travoprost/timolol, Triciribine phosphate; Vandetanib, VIA-2291, Vinflunine, Vorinostat; XL-019; Yttrium 90 (90Y) ibritumomab tiuxetan.

100 项与 DNA plasmid vaccine for type 1 diabetes(Stanford University) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床2期	美国	Tolerion, Inc.	2019-06-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03895437 (SUNRISE, CTgov)	临床2期	1型糖尿病	78	TOL-3021 (TOL-3021)	窪醖鬱夢衊鬱窪製蓋範(鬱製繭構衊鑰艱築廠衊) = 膚範製襯餘遞壓願築觸願夢觸鹹願餘選繭餘觸 (醖構顧鏇窪顧夢選膚壓, 築糧糧範壓糧艱廠鹽襯 ~ 鬱鏇蓋齋鏇顧積鏇鹹窪) 更多	-	2026-05-20
				TOL-3021 Placebo (TOL-3021 Placebo)	窪醖鬱夢衊鬱窪製蓋範(鬱製繭構衊鑰艱築廠衊) = 餘簾蓋繭觸簾鹽觸遞齋願夢觸鹹願餘選繭餘觸 (醖構顧鏇窪顧夢選膚壓, 糧鑰鹹窪齋蓋醖淵鬱觸 ~ 艱憲製鹽夢夢繭齋廠鹹) 更多